Key links in pathogenesis of respiratory failure in COVID-19 and pharmacological correction

  • Received 17.02.2022

  • Revised 25.04.2022

  • Accepted 31.05.2022



  • 1,115 Views

  • Retrieved from Vol. 4, No. 2, 2022

  • Pages 62-74

Summary. COVID-19 pandemic became a game-changer player in the whole world. The severe course of disease manifests with clinical signs of viral pneumonia with an advanced respiratory failure, which can later lead to the development of acute respiratory distress syndrome (ARDS) and fatal consequences. Correct understanding of the key pathophysiological determinants of complications and hypoxemia will contribute to the most rational pharmacotherapy. The aim of the study – to analyze and systematize data on the pathogenesis of ARDS in coronavirus disease and its pharmacological correction. Understanding the key links will make possible not only to identify certain aspects of the treatment, but also to prevent the development of complications. Materials and Methods. Publications of foreign and Ukrainian specialists were analyzed, including databases Medscape/PubMed. Results. An analysis of the key links in the pathogenesis of ARDS, induced by C|OVID-19, the role of the cytokine storm in the progression of the disease and development of arterial hypoxemia and respiratory failure was carried out. An overview of the development and "evolution" of approaches to the treatment of the disease was conducted, starting from attempts to use chloroquine derivatives at the beginning of pandemic to etiotropic treatment with antiviral drugs (such as remdesivir, the combination of lopinavir/ritonavir and paxlovid); biosimilars – monoclonal antibodies and their combinations; prevention and treatment of thrombosis and microthrombosis, which may develop as a result of endothelial dysfunction in such patients, especially in the presence of comorbid pathology (for example, hypertension, diabetes mellitus, obesity). The latest recommendations and American and European protocols for the treatment of coronavirus disease are summarized. Conclusions. The review of the most popular and available medicines and pharmacotherapy for COVID 19 was performed. It indicates the necessity and rationality of finding new, more efficient and less toxic drugs to fight the infection and its complications

COVID-19, pathogenesis, lung failure, cytokines, pharmacological correction, antiviral drugs, monoclonal antibodies

https://doi.org/10.11603/bmbr.2706-6290.2022.2.13082

[1] Wu  Z,  McGoogan  JM.  Characteristics  of  and important  lessons  from  the  coronavirus  disease  2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. jama. 2020;323(13): 1239-42. 

[2] Naidoo J, Wang X, Woo KM, Iyriboz T, Halpenny D, Cunningham J, Chaft JE, Segal NH, Callahan MK, Lesokhin AM, Rosenberg J. Pneumonitis in patients treated with anti–programmed death-1/programmed death ligand 1 therapy. Journal of Clinical Oncology. 2017;35(7): 709.

[3] Bernheim A,  Mei  X,  Huang  M, Yang Y,  Fayad  ZA, Zhang N, Diao K, Lin B, Zhu X, Li K, Li S. Chest CT findings in  coronavirus  disease-19 (COVID-19):  relationship  to duration of infection. Radiology. 2020: 200463.

[4] Gattinoni L, Coppola S, Cressoni M, Busana M, Rossi S,  Chiumello  D.  COVID-19  does  not  lead  to  a  “typical” acute  respiratory  distress  syndrome. American  journal  of respiratory and critical care medicine. 2020;201(10): 1299-300.

[5] Sinha P, Calfee CS. Phenotypes in acute respiratory distress  syndrome:  moving  towards  precision  medicine. Curr Opin Crit Care. 2019;25(1): 12-20. 

[6] Gattinoni L, Chiumello D, Caironi P, Busana M, Romitti F, Brazzi L, Camporota L. COVID-19 pneumonia: different respiratory treatments for different phenotypes? Intensive care medicine. 2020;46(6): 1099-102.

[7] Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R, Niu P. A novel coronavirus from patients  with  pneumonia  in  China,  2019.  N  Engl  J  Med. 2020;382(8): 727-33.

[8] Cressoni  M,  Cadringher  P,  Chiurazzi  C,  Amini  M, Gallazzi E, Marino A, Brioni M, Carlesso E, Chiumello D, Quintel M, Bugedo G. Lung inhomogeneity in patients with acute  respiratory  distress  syndrome. American  journal  of respiratory and critical care medicine. 2014;189(2): 149-58.

[9] Vaporidi  K, Akoumianaki  E,  Telias  I,  Goligher  EC, Brochard L, Georgopoulos D. Respiratory drive in critically ill  patients.  Pathophysiology  and  clinical  implications. American journal of respiratory and critical care medicine. 2020;201(1): 20-32.

[10] Wilkerson RG, Adler JD, Shah NG, Brown R. Silent hypoxia: a harbinger of clinical deterioration in patients with COVID-19. Am J Emerg Med. 2020;38(10): 2243-e5.

[11] Dhont  S,  Derom  E,  Van  Braeckel  E,  Depuydt  P, Lambrecht BN. The pathophysiology of ‘happy’hypoxemia in COVID-19. Respir Res. 2020;21(1): 1-9.

[12] González-Duarte  A,  Norcliffe-Kaufmann  L.  Is "happy  hypoxia"'  in  COVID-19  a  disorder  of  autonomic interoception? A  hypothesis.  Clin Auton  Res.  2020;30(4): 331-3.

[13] Pak AI, Shevchuk OO, Palii SM, Selskyi BP, Korda MM.  Endothelial  dysfunction  at  COVID-19  (Literature review). Ukr med chasop. 2021;3(143)V/VI: 1-7. Ukrainian.

[14] D'Alonzo  GE,  Dantzker  DR.  Respiratory  failure, mechanisms  of  abnormal  gas  exchange,  and oxygen delivery. Med Clin North Am. 1983;67(3): 557-71.

[15] Meng L, Qiu H, Wan L, Ai Y, Xue Z, Guo Q, Deshpande R, Zhang L, Meng J, Tong C, Liu H, Xiong L. Intubation and  Ventilation  amid  the  COVID-19  Outbreak:  Wuhan's Experience. Anesthesiology. 2020 Jun;132(6):1317-32.

[16] Tobin  MJ,  Jubran  A,  Laghi  F.  Respiratory  drive measurements do not signify conjectural patient self-inflicted lung injury. Am J Respir Crit Care Med. 2021;203(1): 142-3

[17] Acute  Respiratory  Distress  Syndrome  Network, Brower RG, Matthay MA, Morris A, Schoenfeld D, Thompson BT,  Wheeler  A.  Ventilation  with  lower  tidal  volumes  as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med. 2000;342(18): 1301-8.

[18] Evora PR, Alves Junior L, Ferreira CA, Menardi AC, Bassetto S, Rodrigues AJ, Scorzoni Filho A, Vicente WV. Twenty  years  of  vasoplegic  syndrome  treatment  in  heart surgery. Methylene blue revised. Rev Bras Cir Cardiovasc. 2015;30(1): 84-92.

[19] Ackermann M, Verleden SE, Kuehnel M, Haverich A, Welte T, Laenger F, Vanstapel A, Werlein C, Stark H, Tzankov A, Li WW, Li VW, Mentzer SJ, Jonigk D. Pulmonary vascular  endothelialitis,  thrombosis,  and  angiogenesis  in Covid-19. N Engl J Med. 2020;383(2): 120-8

[20] Wang Z, Zhang D, Wang S, Jin Y, Huan J, Wu Y, Xia C, Li Z, Qi X, Zhang D, Han X, Zhu X, Qu Y, Wang Q. A Retrospective study from 2 centers in China on the effects of continued use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in patients with hypertension and COVID-19. Med Sci Monit. 2020;26: e926651.

[21] Li J, Wang X, Chen J, Zhang H, Deng A. Association of renin-angiotensin system inhibitors with severity or risk of  death  in  patients  with  hypertension  hospitalized  for Coronavirus Disease 2019 (COVID-19) Infection in Wuhan, China. JAMA Cardiol. 2020;5(7): 825-30. 

[22] Ishiguro  T,  Matsuo  K,  Fujii  S,  Takayanagi  N. Acute  thrombotic  vascular  events  complicating  influenza-associated  pneumonia.  Respir  Med  Case  Rep.  2019;28: 100884.

[23] Thachil J, Tang N, Gando S, Falanga A, Cattaneo M, Levi M, Clark C, Iba T. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J Thromb Haemost. 2020;18(5): 1023-26.

[24] Lippi G, Plebani M, Henry BM. Thrombocytopenia is  associated  with  severe  coronavirus  disease  2019 (COVID-19)  infections:  A  meta-analysis.  Clin  Chim  Acta. 2020;506: 145-8.

[25] Han H, Yang L, Liu R, Liu F, Wu KL, Li J, Liu XH, Zhu CL. Prominent changes in blood coagulation of patients with SARS-CoV-2  infection.  Clin  Chem  Lab  Med.  2020;58(7): 1116-20.

[26] Sinha  P,  Matthay  MA,  Calfee  CS.  Is  a “cytokine storm”  relevant  to  COVID-19?.  JAMA  internal  medicine. 2020;180(9): 1152-4.

[27] Mehta  P,  McAuley  DF,  Brown  M,  Sanchez  E, Tattersall  RS,  Manson  JJ.  COVID-19:  consider  cytokine storm  syndromes  and immunosuppression.  The  Lancet. 2020;395(10229): 1033-4.

[28] Wan S, Yi Q, Fan S, Lv J, Zhang X, Guo L, Lang C, Xiao Q, Xiao K, Yi Z, Qiang M, Xiang J, Zhang B, Chen Y,  Gao  C.  Relationships  among  lymphocyte  subsets, cytokines,  and  the  pulmonary  inflammation  index  in coronavirus (COVID-19) infected patients. Br J Haematol. 2020;189(3): 428-37.

[29] Xu  B,  Fan  CY,  Wang AL,  Zou YL, Yu YH,  He  C, Xia WG, Zhang JX, Miao Q. Suppressed T cell-mediated immunity in patients with COVID-19: A clinical retrospective study in Wuhan, China. J Infect. 2020;81(1): e51-e60

[30] Buszko M, Park JH, Verthelyi D, Sen R, Young HA, Rosenberg AS.The dynamic changes in cytokine responses in COVID-19: A snapshot of the current state of knowledge. Nat. Immunol. 2020,21: 1146-51. 

[31] Kox  M,  Waalders  NJ,  Kooistra  EJ,  Gerretsen  J, Pickkers  P.  Cytokine  levels  in  critically  ill  patients  with COVID-19  and other  conditions.  Jama.  2020;324(15): 1565-7.

[32] Mangalmurti  N,  Hunter  CA.  Cytokine  storms: understanding COVID-19. Immunity. 2020;53(1): 19-25.

[33] Severin R, Arena R, Lavie CJ, Bond S, Phillips SA. Respiratory  muscle performance  screening  for  infectious disease  management  following  COVID-19:  a  highly pressurized situation. Am J Med. 2020;133(9): 1025-32. 

[34] Сarfì  A,  Bernabei  R,  Landi  F.  Gemelli  Against COVID-19  Post-Acute  Care  Study  Group.  Persistent symptoms  in  patients  after  acute  COVID-19.  JAMA. 2020;324 (6): 603-5. 

[35] Adamson CS , Chibale K , Goss RJM , Jaspars M ,  Newman  DJ  ,  Dorrington  RA.  Antiviral  drug  discovery: preparing for the next pandemic. Chem Soc Rev. 2021;50(6): 3647-55

[36] Benlloch  JM,  Cortés  JC,  Martínez-Rodríguez  D, Julián RS, Villanueva RJ. Effect of the early use of antivirals on  the  COVID-19  pandemic.  A  computational  network modeling  approach.  Chaos  Solitons  Fractals.  2020;140: 110168. 

[37] Frediansyah  A,  Tiwari  R,  Sharun  K,  Dhama  K, Harapan H. Antivirals for COVID-19: A critical review. Clin Epidemiol Glob Health. 2021;9: 90-8.

[38] Eastman RT, Roth JS, Brimacombe KR, Simeonov A, Shen M, Patnaik S, Hall MD. Remdesivir: a review of its discovery and development leading to emergency use authorization  for  treatment  of  COVID-19. ACS  Cent  Sci. 2020;6(5): 672-83

[39] Yao TT, Qian JD, Zhu WY, Wang Y, Wang GQ. A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus-A possible reference for coronavirus disease-19 treatment option. J Med Virol. 2020;92(6): 556-63.

[40] Imran M, Kumar Arora M, Asdaq SMB, Khan SA, Alaqel SI, Alshammari MK, Alshehri MM, Alshrari AS, Mateq Ali A, Al-Shammeri AM, Alhazmi  BD,  Harshan AA, Alam MT, Abida. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510125/https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510125/ Molecules. 2021;26(19): 5795.

[41] Painter WP, Holman W, Bush JA, Almazedi F, Malik H, Eraut NCJE, Morin MJ, Szewczyk LJ, Painter GR. Human safety,  tolerability,  and pharmacokinetics  of  molnupiravir, a  novel  broad-spectrum  oral  antiviral  agent  with  activity against  SARS-CoV-2. Antimicrob  Agents  Chemother. 2021;65(5): e02428-20. 

[42] Colson P, Rolain JM, Lagier JC, Brouqui P, Raoult D. Chloroquine and hydroxychloroquine as available weapons to  fight  COVID-19.  Int  J  Antimicrob  Agents.  2020;55(4): 105932.

[43] Choudhary  R,  Sharma  AK.  Potential  use  of hydroxychloroquine,  ivermectin  and  azithromycin  drugs in  fighting  COVID-19:  trends,  scope  and  relevance.  New Microbes New Infect. 2020;35: 100684.

[44] Colson  P,  Rolain  JM,  Raoult  D.  Chloroquine  for the 2019 novel coronavirus SARS-CoV-2. Int J Antimicrob Agents. 2020;55(3): 105923. 

[45] Jawhara  S.  Could  intravenous  immunoglobulin collected  from  recovered  Coronavirus  patients  protect against COVID-19 and strengthen the immune system of new patients? Int J Mol Sci. 2020;21(7): 2272.

[46] Galeotti  C,  Kaveri  SV,  Bayry  J.  Intravenous immunoglobulin immunotherapy for coronavirus disease-19 (COVID-19). Clin Transl Immunology. 2020;16;9(10): e1198.

[47] Channappanavar R, Fehr AR, Zheng J, Wohlford-Lenane C, Abrahante JE, Mack M, Sompallae R, McCray PB  Jr,  Meyerholz  DK,  Perlman  S.  IFN-I  response  timing relative to virus replication determines MERS coronavirus infection outcomes. J Clin Invest. 2019;129(9): 3625-39.

[48] Sainz  B  Jr,  Mossel  EC,  Peters  CJ,  Garry  RF. Interferon-beta and interferon-gamma synergistically inhibit the  replication  of  severe  acute  respiratory  syndrome-associated coronavirus (SARS-CoV). Virology. 2004;329(1): 11-7.
 
[49] Strati P, Ahmed S, Kebriaei P, Nastoupil LJ, Claussen CM, Watson G, Horowitz SB, Brown ART, Do B, Rodriguez MA, Nair R, Shpall EJ, Green MR, Neelapu SS, Westin JR. Clinical efficacy of anakinra to mitigate CAR T-cell therapy-associated  toxicity  in  large  B-cell  lymphoma.  Blood Adv. 2020;4(13): 3123-7. 

[50] Navarro-Millán I, Sattui SE, Lakhanpal A, Zisa D, Siegel CH, Crow MK. Use of Anakinra to prevent mechanical ventilation  in  severe  COVID-19:  A  case  series.  Arthritis Rheumatol. 2020;72(12): 1990-7.

[51] Liu B, Li M, Zhou Z, Guan X, Xiang Y. Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)? J Autoimmun. 2020;111: 102452.

[52] Maeda  T,  Obata  R,  Rizk  DO  D,  Kuno  T.  The association of interleukin-6 value, interleukin inhibitors, and outcomes of patients with COVID-19 in New York City. J Med Virol. 2021;93(1): 463-71. 

[53] Galván-Román   JM,  Rodríguez-García   SC, Roy-Vallejo  E,  Marcos-Jiménez  A,  Sánchez-Alonso  S, Fernández-Díaz  C,  Alcaraz-Serna  A,  et  al.;  REINMUN-COVID  Group.  IL-6  serum  levels  predict  severity  and response  to  tocilizumab  in  COVID-19: An  observational study. J Allergy Clin Immunol. 2021;147(1): 72-80.e8. 

[54] Beović B, Doušak M, Ferreira-Coimbra J, Nadrah K,  Rubulotta  F,  Belliato  M,  Berger-Estilita  J,  Ayoade  F, Rello J, Erdem H. Antibiotic use in patients with COVID-19: a  'snapshot'  Infectious  Diseases  International  Research Initiative  (ID-IRI)  survey.  J  Antimicrob Chemother. 2020;75(11): 3386-90.

[55] Chedid M, Waked R, Haddad E, Chetata N, Saliba G,  Choucair  J.  Antibiotics  in  treatment  of  COVID-19 complications:  a  review  of  frequency,  indications,  and efficacy. J Infect Public Health. 202114(5): 570-6.

[56] Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res. 2020;178: 104787.  

[57] Wu C, Hou D, Du C, Cai Y, Zheng J, Xu J, Chen X,  et  al.  Corticosteroid  therapy  for  coronavirus  disease 2019-related acute respiratory distress syndrome: a cohort study with propensity score analysis. Crit Care. 2020;24(1): 643. 

[58] Hasan SS, Capstick T, Ahmed R, Kow CS, Mazhar F, Merchant HA, Zaidi STR. Mortality in COVID-19 patients with acute respiratory distress syndrome and corticosteroids use:  a  systematic  review  and  meta-analysis.  Expert  Rev Respir Med. 2020;14(11): 1149-63. 

[59] Ye Z,  Wang  Y,  Colunga-Lozano  LE,  Prasad  M, Tangamornsuksan W, Rochwerg B, Yao L, Motaghi S, et al. Efficacy and safety of corticosteroids in COVID-19 based on  evidence  for  COVID-19,  other  coronavirus  infections, influenza, community-acquired  pneumonia  and  acute respiratory  distress  syndrome:  a  systematic  review  and meta-analysis. CMAJ. 2020;192(27): E756-E767. 

[60] Helms  J, Tacquard  C,  Severac  F,  Leonard-Lorant I,  Ohana  M,  Delabranche  X,  Merdji  H,  et  al.;  CRICS TRIGGERSEP Group (Clinical Research in Intensive Care and Sepsis Trial Group for Global Evaluation and Research in Sepsis). High risk of thrombosis in patients with severe SARS-CoV-2  infection:  a multicenter  prospective  cohort study. Intensive Care Med. 2020;46(6): 1089-98. 

[61] Hao C, Xu H, Yu L, Zhang L. Heparin: An essential drug  for  modern  medicine.  Prog  Mol  Biol  Transl  Sci. 2019;163: 1-19.

[62] Tang  N,  Bai  H,  Chen  X,  Gong  J,  Li  D,  Sun  Z. Anticoagulant  treatment  is  associated  with  decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. 2020;18(5): 1094-9. 

[63] Camprubí-Rimblas M, Tantinyà N, Guillamat-Prats R, Bringué J, Puig F, Gómez MN, Blanch L, Artigas A. Effects of nebulized antithrombin and heparin on inflammatory and coagulation alterations in an acute lung injury model in rats. J Thromb Haemost. 2020;18(3): 571-83. 

[64] Xu X, Han M, Li T, Sun W, Wang D, Fu B, Zhou Y, Zheng X, Yang Y, Li X, Zhang X, Pan A, Wei H. Effective treatment  of  severe  COVID-19  patients  with  tocilizumab. Proc Natl Acad Sci U S A. 2020;117(20): 10970-5. 

[65] Price  CC,  Altice  FL,  Shyr  Y,  Koff  A,  Pischel  L, Goshua  G,  Azar  MM,  et  al.  Tocilizumab  Treatment  for Cytokine Release Syndrome in Hospitalized Patients With Coronavirus Disease 2019: Survival and Clinical Outcomes. Chest. 2020;158(4): 1397-408. 

[66] Karimi Zarchi AA, Faramarzi MA, Gilani K, Ghazi-Khansari  M, Ghamami  G,  Amani  A.  N-acetylcysteine-loaded  PLGA  nanoparticles  outperform  conventional N-acetylcysteine in acute lung injuries in vivo. International Journal of Polymeric Materials and Polymeric Biomaterials. 2017;66(9): 443-54.

[67] Puyo C, Kreig D, Saddi V, Ansari E, Prince O. Case report: use of hydroxychloroquine and N-acetylcysteine for treatment of a COVID-19 positive patient. F1000Research. 2020;9: 491.

[68] Nasi  A,  McArdle  S,  Gaudernack  G,  Westman G,  Melief  C,  Rockberg  J, Arens  R,  Kouretas  D,  Sjölin  J, Mangsbo  S.  Reactive  oxygen  species  as  an  initiator  of toxic innate immune responses in retort to SARS-CoV-2 in an  ageing  population,  consider  N-acetylcysteine  as  early therapeutic intervention. Toxicol Rep. 2020;7: 768-71.

[69] van  Doremalen  N,  Bushmaker  T,  Morris  DH, Holbrook  MG,  Gamble A,  Williamson  BN,  Tamin A  et  al. Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1. N Engl J Med. 2020;382(16): 1564-7.

[70] Wu, F., Zhao, S., Yu, B. et al. A new coronavirus associated  with  human  respiratory  disease  in  China. Nature. 2020;579:  265-9.  https://doi.org/10.1038/s41586-020-2008-3.

[71] Ari A. Practical strategies for a safe and effective delivery  of  aerosolized  medications  to  patients  with COVID-19. Respir Med. 2020;167: 105987.

[72] Janowitz  T,  Gablenz  E,  Pattinson  D,  Wang  TC, Conigliaro  J,  Tracey  K,  Tuveson  D.  Famotidine  use  and quantitative symptom  tracking  for  COVID-19  in  non-hospitalised patients: a case series. Gut. 2020;69(9): 1592-7. 

[73] Loffredo  M,  Lucero  H,  Chen  DY,  O'Connell  A, Bergqvist S, Munawar A, Bandara A, et al. The in-vitro effect of famotidine on sars-cov-2 proteases and virus replication. Sci Rep. 2021;11(1): 5433. 

[74] Nehra AK, Alexander JA, Loftus CG, Nehra V. Proton Pump Inhibitors: Review of Emerging Concerns. Mayo Clin Proc. 2018;93(2): 240-6.

[75] Zippi M, Fiorino S, Budriesi R, Micucci M, Corazza I, Pica R, de Biase D, et al. Paradoxical relationship between proton pump inhibitors and COVID-19: A systematic review and  meta-analysis.  World  Journal  of  Clinical  Cases. 2021;9(12): 2763.